ACM
PTCT icon

Advent Capital Management’s PTC Therapeutics PTCT Stock Holding History

Advent Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100
Closed -$6K – 305
2017
Q3 		$6K Buy
+100
New +$1.96K ﹤0.01% 270
2015
Q4 		– Sell
-100
Closed -$42K – 506
2015
Q3 		$42K Buy
+100
New +$4.28K ﹤0.01% 453

Other funds holding PTCT

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Advent Capital Management's PTCT Position: Q4 2017 in Review

Advent Capital Management sold out of PTC Therapeutics (PTCT) in Q4 2017, closing a stake of 10,000 shares — an estimated $200K sold.

Advent Capital Management first reported a position in PTCT in Q3 2015 and held it in 2 quarters. The position peaked at $526K in Q3 2015. 125 funds tracked by Wall St. Rank hold PTCT as of Q4 2017.

  • Advent Capital Management reported no remaining PTC Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Advent Capital Management sold 10,000 PTC Therapeutics shares in Q4 2017, an estimated $200K.
  • Advent Capital Management first reported a position in PTC Therapeutics in Q3 2015 and held it in 2 quarters.
  • Advent Capital Management's PTC Therapeutics position peaked at $526K in Q3 2015.
  • 125 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2017.

Based on Advent Capital Management's 13F filing for Q4 2017, filed 13 Feb 2018.